Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
CytoMed Therapeutics Limited ( (GDTC) ) has shared an announcement.
On January 13, 2026, CytoMed Therapeutics issued a New Year update outlining its operational progress, financial runway, and strategic initiatives, including diversification into cord blood-derived natural killer cell therapies through its LongevityBank subsidiary and ongoing support from Enterprise Singapore. The company reported it has sufficient resources to fund activities for at least a year, is exploring licensing, real estate monetisation and strategic partnerships to strengthen its business with limited dilution, and noted that Chairman Peter Choo intends to increase his shareholding. CytoMed highlighted a December 8, 2025 memorandum of understanding with Universiti Malaya to launch a multi-site first-in-human Phase I trial in Malaysia of its allogeneic unmodified gamma delta T cells (CTM-GDT) for no-option cancer patients, targeting an investigational new drug submission before June 2026, which complements its ongoing Phase I CAR-T γδ T cell trial (CTM-N2D) at National University Hospital Singapore where six patients have been treated. The company also underscored recent preclinical data co-published with MD Anderson Cancer Center in September/October 2025 supporting the potential of its CTM-GDT therapy in acute myeloid leukemia, reinforcing its positioning in off-the-shelf cell therapies. In a notable move aimed at aligning with long-term investors, CytoMed said it plans to seek shareholder feedback on a proposed scheme that would allow shareholders, subject to medical approval and local regulations, to use their shareholdings to gain access to its donor-derived allogeneic unmodified gamma delta T cell treatments, potentially reshaping how patient capital is rewarded and further cementing its Southeast Asia-based, cost-efficient medical tourism proposition in oncology.
The most recent analyst rating on (GDTC) stock is a Sell with a $1.00 price target. To see the full list of analyst forecasts on CytoMed Therapeutics Limited stock, see the GDTC Stock Forecast page.
Spark’s Take on GDTC Stock
According to Spark, TipRanks’ AI Analyst, GDTC is a Neutral.
The score is held down primarily by deteriorating financial performance (sharp revenue decline, large net losses, and negative free cash flow). Technicals also remain weak with the price below key moving averages and negative MACD, while oversold indicators offer only limited near-term support. Valuation is not compelling given the negative P/E and lack of dividend data.
To see Spark’s full report on GDTC stock, click here.
More about CytoMed Therapeutics Limited
CytoMed Therapeutics Limited is a Singapore-based clinical-stage biopharmaceutical company spun out of A*STAR in 2018, focused on developing novel, affordable donor-derived cell-based allogeneic immunotherapies for a broad range of blood and solid tumors using proprietary gamma delta T cell and iPSC-derived gamma delta natural killer T cell technologies. The company operates a low-cost infrastructure in Southeast Asia, is expanding its pipeline via subsidiary LongevityBank’s work on cord blood-derived natural killer cells, and collaborates with institutions such as the National University Hospital Singapore and MD Anderson Cancer Center to advance its oncology programs.
Average Trading Volume: 121,663
Technical Sentiment Signal: Sell
Current Market Cap: $15.49M
For a thorough assessment of GDTC stock, go to TipRanks’ Stock Analysis page.